Folge uns
DE
DE

Eines der Hauptziele von Life4me+ — ist neue Fälle von HIV und anderen STIs, Hepatitis C und Tuberkulose zu verhindern.

Die App hilft, eine Kommunikation zwischen Ärzten und HIV-positiven Menschen aufzubauen. Die App erlaubt Ihnen, einen Zeitplan für Ihre Medikamenteneinnahme bequem zu organisieren – dies geschieht über eine für Dritte nicht nachvollziehbare und personalisierte Erinnerung.

Alle Nachrichten

Archiv

✕
17 März 2019
5453
TAF as PrEP: is efficiency a matter of form?

TAF as PrEP: is efficiency a matter of form?

Two studies of experimental pre-exposure prophylaxis schemes for HIV infection (PrEP) using the drug tenofovir alafenamide (TAF) immediately confirmed the effectiveness of therapy, but yielded conflicting results. According to experts who presented data at the Conference ...
16 März 2019
7598
On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest data of the effectiveness and safety of fostemsavir

On CROI were presented the latest information on studies of fostemsavir, a drug for the treatment of HIV infection of a fundamentally new type. Fostemsavir (FTR) is the first in its class prodrug of the Temsavir attachment inhibitor (TMR). TMR binds to HIV-1 by blocking ...
15 März 2019
5350
One in six South Africans has potential viral resistance to ART

One in six South Africans has potential viral resistance to ART

At the Conference on Retroviruses and Opportunistic Infections (CROI2019), was announced that up to 17% of South African people who had not previously been treated and who had evaded testing for HIV could have a drug-resistant strain of the virus, and more than half of those ...
14 März 2019
5892
MK-8591 implant has been shown to be highly effective at low dosages

MK-8591 implant has been shown to be highly effective at low dosages

#Merck's nucleoside reverse transcriptase translocation inhibitor (NRTTI) MK-8591 (outside the US and Canada - MSD) showed high antiviral activity against HIV-1 with a single dose of 0.5 mg, follows from preliminary results of clinical phase II trials (NCT03272347) presented ...
13 März 2019
5307
Second Generation HIV Maturation Inhibitor Presented in USA

Second Generation HIV Maturation Inhibitor Presented in USA

Dr. Edwin De Jesus of the Orlandian Center for Immunology (USA) last week presented the results of a phase IIa clinical trial of an innovative second-generation HIV maturation inhibitor GSK2838232. The drug, which previously demonstrated a clearly defined preclinical virological ...
12 März 2019
6727
Gilead presented data on the safety of its long-acting ARV drug

Gilead presented data on the safety of its long-acting ARV drug

Last Thursday, March 7, on the closing day of the International Conference on Retroviruses and Opportunistic Infections (CROI2019), the first data on the safety and tolerability of a fundamentally new ART-medication of prolonged action GS-6207 were presented. The development ...
9 März 2019
6119
Mortality from breast cancer is more common among women with HIV

Mortality from breast cancer is more common among women with HIV

According to a cohort study presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019) in Seattle, the mortality rate among HIV-positive women with breast cancer (BC) is higher than among those with a negative status.
8 März 2019
5497
Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%

Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%

According to the latest data presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019), the number of new HIV infections in southern Africa can be significantly reduced by voluntary testing for HIV in communities and immediately sending to treatment ...
8 März 2019
5392
HIV-specific broadly neutralizing antibodies are promising

HIV-specific broadly neutralizing antibodies are promising

#ART has revolutionized the treatment and prevention of HIV infection. However, a violation of the systemic nature of medication use today will almost certainly lead to an increase in viral load. The reason for this is the existence of hidden "tanks". Knowing this, scientists ...
7 März 2019
5318
Expert: it is dangerous to hush up the problem of STI growth against the background of a decrease in HIV cases

Expert: it is dangerous to hush up the problem of STI growth against the background of a decrease in HIV cases

According to experts, with the emergence and growth of the use of new medical and prophylactic drugs, the sexual behavior of both HIV-positive and HIV-negative people who are at risk of infection has changed dramatically. As ARVT improved the quality of life, naturally affecting ...
Wir verwenden Cookies auf dieser Website, um den Besuch unserer Website attraktiv zu gestalten und die Nutzung bestimmter Funktionen zu ermöglichen.
Durch Klicken auf eine beliebige Schaltfläche auf dieser Website geben Sie Ihre Erlaubnis zur Verwendung von Cookies.